Acopair - Tiotropium
Antimuscarinic bronchodilator.
• Over 18 years for maintenance of COPD: by inhalation of powder, one capsule, once daily.
The professional's guide to product selection
The professional's guide to product selection
Antimuscarinic bronchodilator.
• Over 18 years for maintenance of COPD: by inhalation of powder, one capsule, once daily.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Antimuscarinic bronchodilator.
• Over 18 years for maintenance of COPD: by inhalation of powder, one capsule, once daily.
Antimuscarinic bronchodilator.
• Over 18 years: by inhalation of powder, 375 mcg (1 inhalation), twice daily.
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
In the case of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 micrograms every 4 hours and when required, hourly use is occasionally necessary.
In the case of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
For excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
By subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
for maintenance treatment of chronic obstructive pulmonary disease by inhalation of powder
Adult: 1 capsule once daily, each capsule delivers 55 mcg of glycopyrronium bromide (equivalent to 44 mcg of glycopyrronium).
Antimuscarinic bronchodilator.
• Over 18 years for COPD: by inhalation of powder, 55 mcg (1 inhalation), once daily.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Antimuscarinic bronchodilator.
Acute bronchospasm by inhalation of nebulised solution
• Child under 5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Severe or life-threatening acute asthma
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
• Over 18 years for maintenance of COPD or treatment of asthma using Spiriva Respimat: by inhalation, 5 mcg, once daily.
• Child 6-11 years for severe asthma [add-on to inhaled corticosteroid (over 400 micrograms budesonide daily or equivalent) and 1 controller, or inhaled corticosteroid (200–400 micrograms budesonide daily or equivalent) and 2 controllers, in patients who have suffered one or more severe exacerbations in the last year]: 5 mcg, once daily.
• Child 12-17 years for severe asthma [add-on to inhaled corticosteroid (over 800 micrograms budesonide daily or equivalent) and 1 controller, or inhaled corticosteroid (400–800 micrograms budesonide daily or equivalent) and 2 controllers, in patients who have suffered one or more severe exacerbations in the last year]: 5 mcg, once daily.
Adults for maintenance bronchodilator treatment to relieve symptoms of patients with COPD by inhalation of powder, one capsule, once daily.